SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Afaq Sarwar who wrote (2573)1/12/1998 6:04:00 PM
From: Bruce Olsten  Read Replies (1) | Respond to of 3906
 
Afaq, you said you would assume that it covers both the drug and the delivery system and offered to call the company for clarification. This would be good news of monumental importance for HVSF if the delivery system were officially in the clear. However, as Waite did not make any clear and pointed reference to a delivery system patent victory, I am sceptical. Perhaps the press release was intentionally vague on that point? If they were intentionally vague, then you can bet that the tran-urethral aspect is still in legal limbo.

Bruce



To: Afaq Sarwar who wrote (2573)1/12/1998 6:12:00 PM
From: Dan Dieffenwierth  Read Replies (2) | Respond to of 3906
 
Afaq, I saw that post also on the VVUS thread a while back.
I believe it was probably posted by someone who didn't know
what being "continued" meant and thought it meant they
counter sued. So therefore there would be no documentation.
And probably no one over there caught it when it happened.
I too, am feeling more and more confident in the new
management. I can see strength in this one and feel better
about it.
Dan


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News